Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Electronic Message · 1 trial · 2 indications
To determine if electronic reminders coupled with electronic educational messaging can increase HPV vaccine use and adherence among college students in eastern North Carolina.
| Arm | Type | Description |
|---|---|---|
| Electronic Messages | EXPERIMENTAL | Intervention group participants received electronic (text and/or email) reminder messages coupled with health educational messages about HPV and HPV vaccine across 7 months |
| Standard of Care | NO_INTERVENTION | Control group participants received standard of care at the student health center which included a card with their next appointment written on it. |
| Name | Type | Description |
|---|---|---|
| Electronic Message | PROCEDURE | Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design). |
Inclusion Criteria: * Male \& Female Students enrolled at East Carolina University (ECU) Exclusion Criteria: * Non-English speaking students * Students under the age of 18 or over 26 * Individuals not enrolled at ECU
Electronic Message is an investigational intervention being studied for patient compliance, specifically to increase human papillomavirus (HPV) vaccine utilization and adherence among college students. It is a digital messaging approach evaluated in a clinical trial setting to improve health-related behaviors.
Electronic Message is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting research on this digital intervention to assess its impact on patient compliance and vaccine adherence.
Electronic Message is in early Phase 1 clinical development. It has completed one trial, which was an early phase study. The intervention is investigational and has not been approved by regulatory authorities for commercial use.
Electronic Message was studied in clinical trial NCT01568515, titled 'Electronic Messaging to Increase Human Papillomavirus Vaccine Utilization and Adherence Among College Students.' This completed trial enrolled 283 participants and was a randomized, double-blind, no-treatment controlled study.
Electronic Message is not a traditional drug but a digital health intervention. It is being studied for its ability to improve patient compliance and HPV vaccine adherence. Its modality is not specified, and it is evaluated as a behavioral or communication tool rather than a pharmacological agent.